Loading...
Market
Genezen completes acquisition of UniQure facility by end of 2024?
5
Resolution / Starting Odds
Yes • 50%
No • 50%
Company press releases, SEC filings, or news reports
Story
UniQure Sells Lexington Facility to Genezen for $25M, Outsources Hemgenix Manufacturing $QURE
Jul 1, 2024, 03:11 PM
UniQure has announced the sale of its commercial manufacturing facility in Lexington, Massachusetts, to Genezen, a contract development and manufacturing organization (CDMO) specializing in viral vector production. The deal, valued at $25 million, includes stock and debt. This move comes after UniQure laid off one-fifth of its staff and shuttered another research facility in Lexington in October. As part of the transaction, Genezen will acquire UniQure's commercial gene therapy manufacturing operations, which includes the production of Hemgenix. The sale allows UniQure to outsource the manufacturing of Hemgenix, a gene therapy product. The ticker symbols involved are $QURE and $PFE.
View original story
Similar markets
Pharmaceutical company • 25%
Biotechnology company • 25%
Academic institution • 25%
Other • 25%
Below $3 billion • 25%
$3 billion to $5 billion • 25%
$5 billion to $7 billion • 25%
Above $7 billion • 25%
Below $50 • 25%
$50-$74.99 • 25%
$75-$99.99 • 25%
$100 or higher • 25%
Below $30 • 25%
$30-$40 • 25%
$40-$50 • 25%
Above $50 • 25%
Below $50 • 25%
$50 to $75 • 25%
$75 to $100 • 25%
Above $100 • 25%
Yes • 50%
No • 50%
Phase III trial initiation • 25%
FDA accelerated approval • 25%
New interim data release • 25%
Other milestone • 25%
Yes • 50%
No • 50%